Harmony Biosciences Holdings Stock Price To Book

HRMY Stock

USD 38.98 0.10 0.26%

Harmony Biosciences Holdings fundamentals help investors to digest information that contributes to Harmony Biosciences' financial success or failures. It also enables traders to predict the movement of Harmony Stock. The fundamental analysis module provides a way to measure Harmony Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Harmony Biosciences stock.

Other Current Liab Total Assets

Price To Book Ratio is likely to rise to 3.89 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Harmony Biosciences Holdings Company Price To Book Analysis

Harmony Biosciences' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Harmony Biosciences Price To Book

3.73 X

Most of Harmony Biosciences' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Harmony Biosciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Harmony Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for Harmony Biosciences is extremely important. It helps to project a fair market value of Harmony Stock properly, considering its historical fundamentals such as Price To Book. Since Harmony Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Harmony Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Harmony Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Long Term Debt	Intangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Current Deferred Revenue	Short Long Term Debt	Short Term Debt
Total Assets		0.96	0.95	-0.25	0.24	0.87	0.9	0.99	0.92	-0.9	0.88	-0.69	-0.93	0.91	0.89	-0.79	0.92	-0.69	0.88	0.86	0.86
Total Stockholder Equity	0.96		0.95	-0.42	0.47	0.88	0.77	0.94	0.88	-0.81	0.88	-0.72	-0.84	0.79	0.77	-0.81	0.94	-0.72	0.92	0.89	0.89
Net Tangible Assets	0.95	0.95		-0.44	0.31	0.73	0.82	0.97	0.93	-0.93	0.94	-0.59	-0.89	0.89	0.88	-0.7	0.88	-0.59	0.86	0.76	0.76
Net Debt	-0.25	-0.42	-0.44		-0.78	-0.26	0.03	-0.24	-0.28	0.2	-0.32	0.27	0.03	-0.08	-0.05	0.28	-0.29	0.27	-0.31	-0.41	-0.41
Retained Earnings	0.24	0.47	0.31	-0.78		0.46	-0.12	0.15	0.18	0.05	0.23	-0.37	0.02	-0.12	-0.15	-0.37	0.37	-0.37	0.47	0.53	0.53
Accounts Payable	0.87	0.88	0.73	-0.26	0.46		0.69	0.78	0.71	-0.6	0.63	-0.79	-0.7	0.62	0.59	-0.84	0.85	-0.79	0.8	0.98	0.98
Total Liab	0.9	0.77	0.82	0.03	-0.12	0.69		0.92	0.93	-0.92	0.84	-0.41	-0.97	0.96	0.95	-0.52	0.8	-0.41	0.77	0.65	0.65
Net Invested Capital	0.99	0.94	0.97	-0.24	0.15	0.78	0.92		0.94	-0.96	0.92	-0.62	-0.96	0.95	0.94	-0.73	0.89	-0.62	0.85	0.78	0.78
Total Current Assets	0.92	0.88	0.93	-0.28	0.18	0.71	0.93	0.94		-0.92	0.97	-0.4	-0.96	0.92	0.9	-0.53	0.9	-0.4	0.9	0.71	0.71
Capital Stock	-0.9	-0.81	-0.93	0.2	0.05	-0.6	-0.92	-0.96	-0.92		-0.89	0.46	0.94	-0.99	-0.98	0.57	-0.77	0.46	-0.71	-0.61	-0.61
Net Working Capital	0.88	0.88	0.94	-0.32	0.23	0.63	0.84	0.92	0.97	-0.89		-0.37	-0.92	0.88	0.86	-0.51	0.89	-0.37	0.9	0.64	0.64
Common Stock	-0.69	-0.72	-0.59	0.27	-0.37	-0.79	-0.41	-0.62	-0.4	0.46	-0.37		0.42	-0.48	-0.45	0.99	-0.67	1.0	-0.48	-0.8	-0.8
Property Plant Equipment	-0.93	-0.84	-0.89	0.03	0.02	-0.7	-0.97	-0.96	-0.96	0.94	-0.92	0.42		-0.96	-0.95	0.55	-0.85	0.42	-0.84	-0.66	-0.66
Long Term Debt	0.91	0.79	0.89	-0.08	-0.12	0.62	0.96	0.95	0.92	-0.99	0.88	-0.48	-0.96		0.99	-0.59	0.8	-0.48	0.72	0.61	0.61
Intangible Assets	0.89	0.77	0.88	-0.05	-0.15	0.59	0.95	0.94	0.9	-0.98	0.86	-0.45	-0.95	0.99		-0.56	0.76	-0.45	0.71	0.57	0.57
Long Term Debt Total	-0.79	-0.81	-0.7	0.28	-0.37	-0.84	-0.52	-0.73	-0.53	0.57	-0.51	0.99	0.55	-0.59	-0.56		-0.77	0.99	-0.59	-0.85	-0.85
Capital Surpluse	0.92	0.94	0.88	-0.29	0.37	0.85	0.8	0.89	0.9	-0.77	0.89	-0.67	-0.85	0.8	0.76	-0.77		-0.67	0.92	0.85	0.85
Deferred Long Term Liab	-0.69	-0.72	-0.59	0.27	-0.37	-0.79	-0.41	-0.62	-0.4	0.46	-0.37	1.0	0.42	-0.48	-0.45	0.99	-0.67		-0.48	-0.8	-0.8
Current Deferred Revenue	0.88	0.92	0.86	-0.31	0.47	0.8	0.77	0.85	0.9	-0.71	0.9	-0.48	-0.84	0.72	0.71	-0.59	0.92	-0.48		0.78	0.78
Short Long Term Debt	0.86	0.89	0.76	-0.41	0.53	0.98	0.65	0.78	0.71	-0.61	0.64	-0.8	-0.66	0.61	0.57	-0.85	0.85	-0.8	0.78		1.0
Short Term Debt	0.86	0.89	0.76	-0.41	0.53	0.98	0.65	0.78	0.71	-0.61	0.64	-0.8	-0.66	0.61	0.57	-0.85	0.85	-0.8	0.78	1.0

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict Harmony Biosciences

Price Book Value Ratio Over Time

Harmony Book Value Per Share

Book Value Per Share

7.42

At this time, Harmony Biosciences' Book Value Per Share is fairly stable compared to the past year.

Based on the latest financial disclosure, Harmony Biosciences Holdings has a Price To Book of 3.725 times. This is 85.49% lower than that of the Pharmaceuticals sector and 38.33% lower than that of the Health Care industry. The price to book for all United States stocks is 60.83% higher than that of the company.

Harmony Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harmony Biosciences' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harmony Biosciences could also be used in its relative valuation, which is a method of valuing Harmony Biosciences by comparing valuation metrics of similar companies.

Harmony Biosciences is currently under evaluation in price to book category among its peers.

Harmony Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Harmony Biosciences from analyzing Harmony Biosciences' financial statements. These drivers represent accounts that assess Harmony Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Harmony Biosciences' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	2.1B	2.5B	3.3B	1.9B	1.7B	1.8B
Enterprise Value	2.0B	2.4B	3.2B	1.8B	1.6B	1.9B

Harmony Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harmony Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harmony Biosciences' managers, analysts, and investors.

Environmental

Governance

Social

Harmony Fundamentals

	Return On Equity	0.23
	Return On Asset	0.13
	Profit Margin	0.18 %
	Operating Margin	0.33 %
	Current Valuation	2 B
	Shares Outstanding	57.03 M
	Shares Owned By Insiders	11.68 %
	Shares Owned By Institutions	97.95 %
	Number Of Shares Shorted	3.77 M
	Price To Earning	293.37 X
	Price To Book	3.73 X
	Price To Sales	3.26 X
	Revenue	582.02 M
	Gross Profit	536.32 M
	EBITDA	221.51 M
	Net Income	128.85 M
	Cash And Equivalents	254.17 M
	Cash Per Share	4.30 X
	Total Debt	193.57 M
	Debt To Equity	0.79 %
	Current Ratio	4.91 X
	Book Value Per Share	10.46 X
	Cash Flow From Operations	219.39 M
	Short Ratio	6.89 X
	Earnings Per Share	2.11 X
	Target Price	54.22
	Number Of Employees	246
	Beta	0.8
	Market Capitalization	2.22 B
	Total Asset	811.45 M
	Retained Earnings	(143.28 M)
	Working Capital	287.29 M
	Net Asset	811.45 M

About Harmony Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Harmony Biosciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harmony Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harmony Biosciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

Additional Tools for Harmony Stock Analysis

When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC